THE ANALYSIS OF CD44 ALTERNATIVE SPLICING PATTERN IN UROLOGIC CANCER

泌尿系癌症中 CD44 选择性剪接模式的分析

• 批准号: 07671724
• 负责人: MATUI Takashi
• 金额: $ 1.66万
• 依托单位: KOBE UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671724/
• 关键词: UROLOGIC CANCER; CD44; URINE; COMPETITIVE RT-PCR; Competitive RT-PCR; 泌尿器科癌; CD44遺伝子

We have developed CD44-Competitive-RT-PCR which is highly sensitive method enough to detect sparse tumor cells overexpressing CD44R1 among a much larger population of non-neoplastic cells. This technique was applied to 50 urine specimens to investigate whether the detection of tumor cells could be clinically useful in diagnosing cancer. The relative expression of CD44R1 to CD44R2 transcript can be quantified by CD44-Competitive-RT-PCR using endogenous CD44R2 transcript as the internal standard competitor RNA.In 30 specimens with no evidence of neoplasia, the ratio does not exceed 1. On the other hand, in the remaining 20 specimens from patients with urinary tract cancer, the CD44-competitive-RT-PCR assay correctly identified 13 specimens. The sensitivity and specificity of this assay for a diagnosis of cancer was 65% and 100%, respectively.

我们已经开发了CD 44-竞争性RT-PCR，这是一种高灵敏度的方法，足以在更大的非肿瘤细胞群体中检测过表达CD 44 R1的稀疏肿瘤细胞。该技术应用于50份尿液标本，以研究肿瘤细胞的检测是否可用于临床诊断癌症。以内源性CD 44 R2转录本为内标竞争RNA，通过CD 44竞争性RT-PCR定量检测CD 44 R1与CD 44 R2转录本的相对表达，在30例无肿瘤证据的标本中，该比值不超过1。另一方面，在其余20例泌尿道癌患者的标本中，CD 44竞争性RT-PCR检测正确鉴定了13例标本。该检测诊断癌症的灵敏度和特异性分别为65%和100%。